SCHEMBL19859703

SCHEMBL19859703

C[C@]1(F)[C@H](n2cnc3c(N)nc(N)nc32)O[C@](F)(CO)[C@H]1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 4/20 0.46
▸ AHCY P23526 1/20 0.46
▸ HSP90B1 P14625 2/20 0.42
▸ ADA P00813 1/20 0.41
▸ NT5E P21589 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ CDK1 P06493 1/20 0.40
▸ CCNB1 P14635 1/20 0.40
▸ CCNE1 P24864 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ HINT1 P49773 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ ADORA3 P0DMS8 4/20 0.38
▸ ADORA1 P30542 2/20 0.38
▸ HSP90AA1 P07900 1/20 0.38
▸ PDE2A O00408 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ PDE3A Q14432 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31228204 0.90 ADORA2A (0.50) ADORA2AAHCYHSP90B1ADANT5E
SCHEMBL21015191 0.88 ADORA3 (0.53) ADORA2AAHCYADORA3ADORA1
SCHEMBL19778486 0.88 HTR2C (0.41) ADORA2AAHCYHSP90B1ADACYP2C19
SCHEMBL16647595 0.87 ADORA2A (0.39) ADORA2AAHCYHSP90B1ADANT5E
SCHEMBL19778101 0.86 TLR9 (0.39) ADORA2AAHCYNT5ECYP2C19ADORA3
SCHEMBL19777952 0.86 ADORA2A (0.36) ADORA2AAHCYHSP90B1ADAHINT1
SCHEMBL19859736 0.86 ADORA2A (0.57) ADORA2AAHCYADORA3ADORA1
SCHEMBL19778108 0.83 CCNE2 (0.37) ADORA2AAHCYADANT5ECDK1
SCHEMBL19778494 0.83 CCNE2 (0.37) ADORA2AAHCYADANT5ECDK1
SCHEMBL21078466 0.83 AHCY (0.43) ADORA2AAHCYHSP90B1ADANT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3497111-A2 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen BioPharma, Inc. (US) 2019-06-19 — — EP disclosed
US-20190169221-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2019-06-06 — — US disclosed
US-20190169221-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2019-06-06 — — US disclosed
WO-2018031818-A2 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2018-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190169221-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C3B ADORA2A 71/4885AHCY 444/4885HSP90B1 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback